Platelet factor 4

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

Retrieved on: 
Wednesday, February 16, 2022
Deutsch, Millipore, Angiotensin, Tissue, Systematic review, Merck, Company, Journal, PCT, Toxic shock syndrome toxin, OTCQB, ACE2, Blood, Vaccine, RNA transfection, Hematology-Oncology and Stem Cell Transplantation Research Center, Report, Gastrointestinal tract, Platelet factor 4, DNP, COVID-19 vaccine, Liver, Myocardial infarction, FRA, Angiotensin-converting enzyme 2, CDMO, Ohio State University, RBD, Myocarditis, Mouse, CSE, Pericarditis, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, Thrombosis, II, Heart, Pharmaceutical industry, BC

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding suggests that the Company's haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines. Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.

Key Points: 
  • Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • The Biovaxys vaccine for Covid-19, BVX-0320, comprises a portion of the SARS-CoV-2 spike protein that is modified by the hapten, dinitrophenyl (DNP); hapten modification prevents ACE2 binding while retaining immunogenicity.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

Retrieved on: 
Wednesday, February 16, 2022
Deutsch, Millipore, Angiotensin, Tissue, Systematic review, Merck, Company, Journal, PCT, Toxic shock syndrome toxin, OTCQB, ACE2, Blood, Vaccine, RNA transfection, Hematology-Oncology and Stem Cell Transplantation Research Center, Report, Gastrointestinal tract, Platelet factor 4, DNP, COVID-19 vaccine, Liver, Myocardial infarction, FRA, Angiotensin-converting enzyme 2, CDMO, Ohio State University, RBD, Myocarditis, Mouse, CSE, Pericarditis, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, Thrombosis, II, Heart, Pharmaceutical industry, BC

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding suggests that the Company's haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines. Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.

Key Points: 
  • Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • The Biovaxys vaccine for Covid-19, BVX-0320, comprises a portion of the SARS-CoV-2 spike protein that is modified by the hapten, dinitrophenyl (DNP); hapten modification prevents ACE2 binding while retaining immunogenicity.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.

Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs

Retrieved on: 
Thursday, September 23, 2021
Angiotensin, Merck, University, Safety, University of Colorado School of Medicine, Platelet factor 4, Pediatric emergency medicine, Vaccine, Olfactory toxicity in fish, AstraZeneca, Heart, CEO, BioNTech, Journal, NYSE, Myocarditis, Vaccination, WuXi Biologics, Clinical trial, RNA transfection, Pfizer–BioNTech COVID-19 vaccine, Pediatrics, NASDAQ, FDA, Ohio State University, Toxicity, Nobel, Company, Health Canada, Risk, BNTX, Millipore, Severe acute respiratory syndrome coronavirus 2, Hapten, ACE2, II, Parent, News, Limited partnership, CSE, COVID-19, MD, Minister of Health (Canada), Hematology-Oncology and Stem Cell Transplantation Research Center, Research, Ohio, PFE, Pharmaceutical industry

Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike proteinwhich are found in currently available vaccines.

Key Points: 
  • Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike proteinwhich are found in currently available vaccines.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • Biovaxysbelieves that the haptenized spike protein has much diminished ability to bind to ACE2, which would result in much diminished vaccine toxicity.
  • "The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects."

Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs

Retrieved on: 
Thursday, September 23, 2021
Angiotensin, Merck, University, Safety, University of Colorado School of Medicine, Platelet factor 4, Pediatric emergency medicine, Vaccine, Olfactory toxicity in fish, AstraZeneca, Heart, CEO, BioNTech, Journal, NYSE, Myocarditis, Vaccination, WuXi Biologics, Clinical trial, RNA transfection, Pfizer–BioNTech COVID-19 vaccine, Pediatrics, NASDAQ, FDA, Ohio State University, Toxicity, Nobel, Company, Health Canada, Risk, BNTX, Millipore, Severe acute respiratory syndrome coronavirus 2, Hapten, ACE2, II, Parent, News, Limited partnership, CSE, COVID-19, MD, Minister of Health (Canada), Hematology-Oncology and Stem Cell Transplantation Research Center, Research, Ohio, PFE, Pharmaceutical industry

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- USA News Group  -  Despite the approval for the Comirnaty vaccine from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) by the FDA back in August, vaccine hesitancy in the USA persists and is unlikely to disappear. Now with what PFE/BNTX are calling encouraging results for their Covid-19 vaccine trial on kids in hand, it's expected that parents are going to be even more hesitant to jab their own children. Reports of heart inflammation are adding fuel to the fire, spurning closer studies into myocarditis risk taking place inIsrael and the USA, and Canada particularly with mRNA vaccines such as those from Pfizer, BioNTech and Moderna, Inc. (NASDAQ:MRNA), while earlier this year multiple European countries suspended the use of AstraZeneca PLC (NASDAQ:AZN) over worries about blood clots. While these manufacturers are standing by their safety and efficacy, a new study on the hapten-modified spike protein used in the BVX-0320 SARS-CoV-2 vaccine from BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF) is giving hope to another method that could potentially mitigate some of these abnormal life-threatening side effects.

Key Points: 
  • Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike proteinwhich are found in currently available vaccines.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • Biovaxysbelieves that the haptenized spike protein has much diminished ability to bind to ACE2, which would result in much diminished vaccine toxicity.
  • "The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects."

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

Retrieved on: 
Thursday, September 23, 2021
Technology, WuXi Biologics, Patent, News, Clinical trial, OTCQB, Hematology-Oncology and Stem Cell Transplantation Research Center, Vaccine, Deutsch, II, DNP, Fish acute toxicity syndrome, CDMO, CSE, COVID-19, Patient, Angiotensin, MD, Private Securities Litigation Reform Act, Heart, Toxicity, Marketing, Immunotherapy, FRA, Legislation, Company, Merck, Risk, Journal, Millipore, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Human, Hapten, RBD, ACE2, Forward-looking statement, Platelet factor 4, Myocarditis, Pharmaceutical industry

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Key Points: 
  • Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized.
  • BioVaxys is currently finalizing arrangements with a major US academic research institution who will be collaborating with the Company on the study.

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

Retrieved on: 
Thursday, September 23, 2021
Technology, WuXi Biologics, Patent, News, Clinical trial, OTCQB, Hematology-Oncology and Stem Cell Transplantation Research Center, Vaccine, Deutsch, II, DNP, Fish acute toxicity syndrome, CDMO, CSE, COVID-19, Patient, Angiotensin, MD, Private Securities Litigation Reform Act, Heart, Toxicity, Marketing, Immunotherapy, FRA, Legislation, Company, Merck, Risk, Journal, Millipore, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Human, Hapten, RBD, ACE2, Forward-looking statement, Platelet factor 4, Myocarditis, Pharmaceutical industry

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Key Points: 
  • Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized.
  • BioVaxys is currently finalizing arrangements with a major US academic research institution who will be collaborating with the Company on the study.